CRON — Cronos Share Price
0.000.00%
Last trade - 00:00HealthcareAdventurousMid CapNeutral
- $662.53m
- -$175.45m
- $91.90m
- 87
- 32
- 47
- 57
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.59 | ||
| Price to Tang. Book | 0.6 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 7.61 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -14.24% | ||
| Return on Equity | -12.65% | ||
| Operating Margin | -184.96% | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 12.12 | 23.75 | 46.72 | 74.44 | 91.9 | 99.62 | 124.14 | 96.39% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Cronos Group Inc. is a cannabinoid company. The Company is focused on cannabis research, technology and product development. The Company’s portfolio includes PEACE NATURALS, COVE, Spinach, Lord Jones, Happy Dance and PEACE+. PEACE NATURALS a global wellness platform. The COVE and Spinach are adult-use brands. The Lord Jones, Happy Dance and PEACE+ are hemp-derived cannabidiol (CBD) brands. The Company’s segments include United States and Rest of World. The United States operating segment consists of the manufacture and distribution of hemp-derived CBD infused products. The Rest of World operating segment is involved in the cultivation, manufacture, and marketing of cannabis and cannabis-derived products for the medical and adult-use markets. The Company’s subsidiaries include Cronos Israel G.S. Cultivation Ltd, Cronos Israel G.S. Manufacturing Ltd., Cronos Israel G.S. Store Ltd. and Cronos Israel G.S. Pharmacy Ltd.
Directors
- Michael Gorenstein CHM (34)
- Kurt Schmidt PRE (64)
- Robert Madore CFO (56)
- Xiuming Shum EVP (35)
- Shannon Buggy SVP (51)
- Anna Shlimak SVP (35)
- Summer Frein GMG (37)
- Jeffrey Jacobson GMG (35)
- James Rudyk LED (54)
- Jason Adler IND (49)
- Kendrick Ashton IND (45)
- Jody Begley IND (49)
- Murray Garnick IND (61)
- Heather Newman IND (44)
- Last Annual
- December 31st, 2022
- Last Interim
- March 31st, 2023
- Incorporated
- July 9th, 2020
- Public Since
- March 10th, 2020
- No. of Employees
- 626
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 380,815,921
- Address
- 111 Peter Street, Suite 300, TORONTO, M5V2H1
- Web
- https://thecronosgroup.com/
- Phone
- +1 4165040004
- Auditors
- KPMG LLP
Upcoming Events for CRON
Cronos Group Inc Annual Shareholders Meeting
Q2 2023 Cronos Group Inc Earnings Release
Q3 2023 Cronos Group Inc Earnings Release
Similar to CRON
ADMA Biologics
NASDAQ Global Market
Alimera Sciences
NASDAQ Global Market
ANI Pharmaceuticals
NASDAQ Global Market
Aptorum
NASDAQ Global Market
Aquestive Therapeutics
NASDAQ Global Market
FAQ
What is the Cronos share price?
As of Today at 13:05 UTC, shares in Cronos are trading at $1.74. This share price information is delayed by 15 minutes.
How has the Cronos share price performed this year?
Shares in Cronos last closed at $1.74 and the price had moved by -39.16% over the past 365 days. In terms of relative price strength the Cronos share price has underperformed the S&P500 Index by -39.8% over the past year.
What are the analyst and broker recommendations for Cronos?
The overall consensus recommendation for Cronos is Hold. You can view the full broker recommendation list by unlocking its StockReport.
What is the Cronos dividend yield?
Cronos does not currently pay a dividend.
Does Cronos pay a dividend?
Cronos does not currently pay a dividend.
When does Cronos next pay dividends?
Cronos does not currently pay a dividend.
How do I buy Cronos shares?
To buy shares in Cronos you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Cronos?
As of the previous close price of $1.74, shares in Cronos had a market capitalisation of $662.53m.
Where are Cronos shares listed?
Here are the trading details for Cronos:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: CRON
What kind of share is Cronos?
Based on an overall assessment of its quality, value and momentum Cronos is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Cronos share price forecast for 2023?
The analyst consensus target price for shares in Cronos is $2.57. That is 47.65% above the last closing price of $1.74.
Analysts covering Cronos currently have a consensus Earnings Per Share (EPS) forecast of -$0.15 for the next financial year.
What is the trend in the Cronos share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Cronos. Over the past six months, its share price has underperformed the S&P500 Index by -52.36%.
As of the last closing price of $1.74, shares in Cronos were trading -30.66% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Cronos PE Ratio?
The Cronos PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.74.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Cronos?
Cronos' management team is headed by:
- Michael Gorenstein - CHM
- Kurt Schmidt - PRE
- Robert Madore - CFO
- Xiuming Shum - EVP
- Shannon Buggy - SVP
- Anna Shlimak - SVP
- Summer Frein - GMG
- Jeffrey Jacobson - GMG
- James Rudyk - LED
- Jason Adler - IND
- Kendrick Ashton - IND
- Jody Begley - IND
- Murray Garnick - IND
- Heather Newman - IND